A Study of Pemetrexed in Children With Recurrent Cancer

Not Recruiting

Trial ID: NCT00520936


To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma, medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.

Official Title

A Phase II Study of Pemetrexed in Children With Recurrent Malignancies

Stanford Investigator(s)


Inclusion Criteria:

   - Patients must have osteosarcoma, Ewing's sarcoma, medulloblastoma, neuroblastoma,
   rhabdomyosarcoma, ependymoma or high-grade non-brainstem glioma

   - Measurable disease

   - Eastern Cooperative Oncology Group (ECOG) performance 0,1,2

   - Adequate renal, liver and bone marrow function

   - Patient's current disease state must be one with no known curative therapy or therapy
   proven to prolong survival with an acceptable quality of life

Exclusion Criteria:

   - Growth factors that support platelet or white cell number or function must not have
   been administered within the last 7 days prior to enrollment (14 days if Neulasta)

   - Patients with central nervous system (CNS) tumors who have not been on a stable or
   decreasing dose of dexamethasone or other corticosteroid for 7 days prior to

   - Patients with uncontrolled infection

   - Patients who have received pemetrexed previously

   - Patients with pleural effusions or ascites


drug: pemetrexed

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jennifer Lew

New Trial Alerts

Receive email alerts when trials open to patients.